page header

Contents  ·  Introduction  ·  Learning  Objectives  ·  Textbook  ·  Lectures  ·  Procedures  ·  Final Exam  ·  Library  ·  Laboratory  ·  Pharmacy  ·  Imaging  ·  Forms  ·  Videos  ·  About  ·  Contact Us>

Pyrazinamide (Canadian brand: Tebrazid)

Category:

  • Miscellaneous

Description:

  • Antituberculosis agent

Indications:

  • Active tuberculosis (as part of a 6 month regimen consisting of isoniazid, rifampin, and pyrazinamide given for 2 months, followed by isoniazid and rifampin for 4 months)

  • After treatment failure with other primary drugs in any form of active tuberculosis

Contraindications:

  • Severe liver disease

  • Acute gout

Precautions:

  • Pregnancy category C; excreted into breast milk

  • History of gout, renal and hepatic function impairment

  • Alcoholism, elderly

  • HIV, infection (may require longer courses of therapy), diabetes mellitus

Adverse Reactions (Side Effects):

  • CNS: fever

  • GI: anorexia, hepatotoxicity, nausea, vomiting

  • GU: dysuria, interstitial nephritis (rare)

  • HEME: blood clotting abnormalities, increased serum iron concentration, porphyria, sideroblastic anemia, thrombocytopenia

  • METAB: gout, hyperuricemia

  • MS: arthralgia, myalgia

  • SKIN: acne, photosensitivity, pruritus, rash, urticaria

Dosage:

Administered orally

  • Adult:   PO 15-30 mg/kg  every day for 1st 2 months of 6 month regimen with isoniazid and rifampin or as part of an individualized regimen for drug-resistant disease, max 2g daily; alternatively 50-70 mg/kg can be given twice weekly to improve compliance (base dose on lean body weight)

  • Child:   PO 15-40 mg/kg/day divided every 12-24 hours, max 2g daily; alternatively 50-70 mg/kg based on lean body weight twice weekly, max 3g dose

 

 

 


The information contained here is an abbreviated summary. For more detailed and complete information, consult the manufacturer's product information sheets or standard textbooks

Source: Operational Medicine 2001,  Health Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington, D.C., 20372-5300

This information is provided by The Brookside Associates.  The Brookside Associates, LLC. is a private organization, not affiliated with any governmental agency. The opinions presented here are those of the author and do not necessarily represent the opinions of the Brookside Associates or the Department of Defense. The presence of any advertising on these pages does not constitute an endorsement of that product or service by either the US Department of Defense or the Brookside Associates. All material presented here is unclassified.

C. 2009, 2014, All Rights Reserved

brookside associates logo

 

 

 

 

 

Advertise on this site